ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0573

Telehealth versus Outpatients Clinic Follow up in Rheumatoid Arthritis Patients a Randomized Controlled Study

Anne Bull Haaversen1, Inge Christoffer Olsen2, Maiju Pesonen3, Andreas Diamantopoulos4 and jannicke Sundsby karlengen5, 1Martina Hansens Hospital, Hosle, Norway, 2Oslo University Hospital, Oslo, Nepal, 3Oslo University, Oslo, Norway, 4Akershus University Hospital, Lørenskog, Norway, 5Martina Hansens Hospital, Baerum, Norway

Meeting: ACR Convergence 2022

Keywords: quality of care, Randomized Trial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Measures and Measurement of Healthcare Quality

Session Type: Abstract Session

Session Time: 8:00AM-9:00AM

Background/Purpose: Most Rheumatoid Arthritis (RA) patients are in remission or low disease activity. Yet, RA patients continue to be followed up by pre-scheduled visits, which may compromise accessibility for the sickest and, thus, quality of care. A Patient-Reported Outcome (PRO)-based telehealth (TH) follow-up among RA patients achieved similar disease control as conventional outpatient (OC) follow-up (1).This study compared the effect of a PRO-based TH to a pre-scheduled OC follow-up to monitor disease activity in Norwegian RA patients (TH follow-up was not inferior to OC follow-up).

Methods: Patients with RA in remission or low disease activity defined as a Routine Assessment of Patient Index Data 3 (RAPID3) < 6 were recruited at the Martina Hansens Hospital, Bærum, Norway, between May and June 2020. The patients were randomized to follow-up by either TH or OC. The primary endpoint was an occurrence of flare within 52 weeks, defined as a RAPID3 score of >6 at any measurement between randomization and 52 weeks. All patients, with a reported RAPID3 score >6 were evaluated by a rheumatologist who decided if they had a clinical flare. The occurrence of clinical flare, and satisfaction rates with the follow-up procedures (measured by a Visual Analogue Scale –VAS) among the two patient groups were also compared. The primary endpoint was analyzed using logistic regression adjusted for baseline scores and serotype.

Results: Two hundred twelve patients were recruited, 104 in the OC arm and 108 in the TH arm. All patients fulfilled the ACR/EULAR 2010 classification criteria for RA. The baseline characteristics are presented in Table 1.

Based on RAPID3, 11 patients (5%) flared in the OC group while 27 patients flared in the TH group (13%), with an adjusted risk difference (ARD) of 0.14 (95% CI 0.04- 0.23). Thus, the primary objetive (non-inferiority of the TH group) was not met. Regarding the clinical flare, ten patients (5%) had a clinical flare in the OC group compared to 15 patients (7%) in the TH group (ARD 0.04 (95% CI -0.05-0.13). The mean VAS satisfaction scores at 12 months in TH and OC groups were 8.8 and 9.8, respectively, with an estimated adjusted mean difference (TH-OC) of -0.82 (-1.19, -0.47). Thus, the satisfaction with the follow-up at 12 months was significantly lower in the TH group. The main reason for the lower satisfaction rates in the TH group was the procedure to log in to the application, which many patients found complicated.

Conclusion: TH follow-up seems to have a significantly higher flare rate than the OC follow-up. Yet, no difference was observed concerning clinical flares. One explanation for the higher flare rate defined by the RAPID3 score is that many of the issues reported through the app were not attributed to RA (e.g., osteoarthritis pain). The lower satisfaction rates in the TH group illustrate that technological solutions need to be patient-friendly.

Supporting image 1

Table1. Baseline characteristics


Disclosures: A. Bull Haaversen, None; I. Olsen, None; M. Pesonen, None; A. Diamantopoulos, GE Royalties for lectures; j. Sundsby karlengen, None.

To cite this abstract in AMA style:

Bull Haaversen A, Olsen I, Pesonen M, Diamantopoulos A, Sundsby karlengen j. Telehealth versus Outpatients Clinic Follow up in Rheumatoid Arthritis Patients a Randomized Controlled Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/telehealth-versus-outpatients-clinic-follow-up-in-rheumatoid-arthritis-patients-a-randomized-controlled-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/telehealth-versus-outpatients-clinic-follow-up-in-rheumatoid-arthritis-patients-a-randomized-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology